Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
5 Years : From Feb 2012 to Feb 2017
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, President, Myriad Genetic Laboratories, Inc., is scheduled to present at the Cowen and Company 32nd Annual Health Care Conference, at 8:00 a.m. Eastern Time on Tuesday, March 6, 2012. The conference is being held at The Boston Marriott Copley Place Hotel in Boston, Massachusetts.
The presentation will be available to interested parties through a live webcast accessible on the investor relations section of Myriad's website at www.myriad.com.
About Myriad Genetics
Myriad Genetics, Inc. (Nasdaq:MYGN) is a leading molecular diagnostic company dedicated to developing and marketing transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess a patient's risk of disease progression and disease recurrence. Myriad's portfolio of nine molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a focus on improving an individual's decision making process for monitoring and treating disease. With fiscal year 2011 annual revenue of over $400 million and more than 1,000 employees, Myriad is working on strategic directives, including new product introductions, companion diagnostics, and international expansion, to take advantage of significant growth opportunities. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
CONTACT: Rebecca Chambers
Director, Investor Relations and Corporate Communications